University of Pennsylvania Study Links Prostate Cancer Treatment To Dementia
Here's yet another thing for men with prostate cancer to worry about. A second study has found a connection between treatments that target male hormones and dementia.
Earlier research by a team from the University of Pennsylvania and Stanford University found increased risk for Alzheimer's disease. The new study, from the same institutions, published Thursday in JAMA Oncology, found that patients who had taken androgen deprivation therapy (ADT) had double the risk for a broader range of dementia diagnoses, including Alzheimer's, senile dementia, vascular dementia, and frontotemporal dementia, compared with similar men with prostate cancer who did not have the treatment. The study was based on an analysis of the medical records of more than 9,000 men with prostate cancer from the Stanford University health system from 1994 to 2013. Of those patients, 1,826 had received ADT.
Earlier research by a team from the University of Pennsylvania and Stanford University found increased risk for Alzheimer's disease. The new study, from the same institutions, published Thursday in JAMA Oncology, found that patients who had taken androgen deprivation therapy (ADT) had double the risk for a broader range of dementia diagnoses, including Alzheimer's, senile dementia, vascular dementia, and frontotemporal dementia, compared with similar men with prostate cancer who did not have the treatment. The study was based on an analysis of the medical records of more than 9,000 men with prostate cancer from the Stanford University health system from 1994 to 2013. Of those patients, 1,826 had received ADT.